CURRICULUM VITAE

NAME: The Rev. Prof. Peter U. Nwangwu, M.Sc., Pharm.D., Ph.D., Th.D., D.D.

DATE AND PLACE OF BIRTH: June 13, 1949; at Umuahia, Abia State.

MAILING ADDRESS: P.O. Box 3003

University of Nigeria, Nsukka, Enugu State

TELEPHONE NUMBER: 08060493334

E-MAIL: punwangwu@hotmail.com, or nwangwu@nwangwu.com

WEB SITE: www.nwangwu.com

NATIONALITY: Nigerian - American

MARITAL STATUS: Married, to Patience Ozoemena Nwangwu

NUMBER & AGES OF CHILDREN: Six Children: David (29), Daniel (28), Joy (26)
Paul (22), Sidney (18), Timothy (15)

AREA OF STUDIES: Cardiovascular Pharmacology, Pharmacodynamics and

Toxicology, Biopharmaceutics, Clinical Pharmacy,
Chemistry, Biomedicinal Chemistry, Medical Sciences, and
Theology

EDUCATION:

Institution Degree Year Field

North Carolina
College of Theology D.D 2008 Divinity

North Carolina
College of Theology Th.D 2006 Theology

University of Nebraska Ph.D. 1979 Medical Sciences with

Medical Center Emphasis on Pharmacology

University of Nebraska Pharm.D. 1979 Clinical Pharmacy

Medical Center

University of Nebraska M.Sc. 1976 Pharmacodynamics and

Medical Center Toxicology, and Biomedicinal
Chemistry

University of Nebraska B.A. 1974 Chemistry

Lincoln

1
PROFESSIONAL LICENSURE AND BOARD CERTIFICATIONS:

1. Registered Pharmacist
- State of Nebraska, License No. 9412, since 1981 till current
- State of Texas, License No. 32557, since 1991 till current
2. Fellow, American College of Clinical Pharmacology, since October 14, 1983
3. Fellow, American Society of Consultant Pharmacists, since 1983
4. Fellow, American College of Tropical Medicine, since 1983
5. Ordained Clergy, Church of Nigeria (Anglican Communion) Diocese of Nsukka

SUMMARY OF QUALIFICATIONS:

 Healthcare scientist with very strong interdisciplinary academic and research

preparation. Significant research experience in both academia and industry;
history of productive and relevant research experience in both clinical research
and basic laboratory research.

 Extensive graduate school training which is very broad in scope and depth
(M.S., Pharm.D., Ph.D.), covering both clinical and basic health sciences.
Commitment to academic and research excellence, and have served on the
graduate faculty at two large U.S. universities.

 Over 30 years of professional experience and 25 years of senior management

experience which includes Director of Clinical Research at the University,
Clinical Research Monitor at a multi-billion dollar, multi-national drug
company, and President and CEO of companies in a variety of industrial sectors,
including President and CEO of a drug manufacturing company.

 Warm-blooded entrepreneur adept with new venture creation, and managing

multiple tasks simultaneously, comfortably. Excellent skills in strategic
planning, complex contract negotiations with government agencies and industry,
eminent with creation and articulation of strong visions, and energetic
implementation of program goals, timely. Passionate and intense advocate of
economic development activities.

 Developer of patented products at a U.S. university, therefore have ample

practical experience with intellectual property development, technology transfer,
and research commercialization. As a research scientist who has applied for and
received significant research funding from the U.S. National Institute of Health
(N.I.H.), have practical experience and solid understanding of applicable
regulations and procedures governing research and research funding at the
university.

 Organized and directed a National Symposium on “Concepts and Strategies in

Clinical Research” at Waldorf Astoria Hotel, New York, while on the faculty of
St. John’s University New York. The symposium was co-sponsored by The
United States Pharmaceutical Manufacturers Association and American
Federation for Clinical Research.

2
SKILLS AND ACCOMPLISHMENTS

 An exceptionally charismatic and engaging leader who is very articulate and

quite proficient in building consensus with internal and external constituencies.
Preeminent interpersonal team building skills, and a leadership style
characterized by dialogue and inclusion. Excellent written and oral
communication skills.

 Potent and dynamic self-initiator with strong history of setting very high and
difficult goals, and accomplishing those goals as scheduled. Few examples
include, completed undergraduate studies on Honour roll in two years with a
degree in chemistry from the University of Nebraska, Lincoln. Was the first
student in the history of the University of Nebraska allowed to enroll in and
complete simultaneously the dual doctorate degrees, Pharm.D., and Ph.D.

 Invented a new technique for screening antiarrhythmic drugs which received

worldwide acceptance and became popular worldwide; the technique is still used
in several pharmaceutical companies and pharmacology laboratories as a
standard screening technique for antiarrhythmic drugs, “A rapid in vivo
Technique for Preliminary Screening of Antiarrhythmic Agents in Mice.” Arch.
Int. Pharmacodyn. Therap. 229, 219 (1977).

 Developed and characterized seven new antiarrhythmic drugs protected by U.S.

patents.

 Invented a new technique for identification of time of myocardial infarction

employing TC-99 pyrophosphate, “A Rapid Technique for Identification of Time
of Myocardial Infarction Employing TC-99 pyrophosphate,” Current
Therapeutic Research 30:122 (1981).

 Documented and published the first in vivo murine ventricular tachycardia in a

single surface electrocardiogram lead, which has become a relevant murine
model of human cardiomyopathy for significant studies in cardiovascular
disease worldwide. See citations and references to my research publication by
renowned scientists such as investigators at Harvard Medical School and
University of Pennsylvania in recent publications like: Maguire, Colin T.,
Hiroko Wakimoto, Vickas V. Patel, Peter F. Hammer, Kimberlee Gauvreau, and
Charles I. Berul, “Implications of ventricular arrhythmia vulnerability during
murine electrophysiology studies”. Physiol. Genomics, 15:84-91, 2003.

 Served as the program director, NBC national television series on New Drug
Development, (NBC Host Frank Fields, New York, New York). Program
numbers 4/77 to 4/81, which were broadcasted nationwide on the NBC
television series, “Health Fields”.

3
 My book, “Concepts and Strategies in New Drug Development,” P.U.
Nwangwu, Pharm.D., Ph.D., Praeger Publishers, New York (1983), is used
widely as a training and reference text in the major pharmaceutical industries of
the world, and as a textbook in many post graduate Clinical Pharmacology
training programs at U.S. and European universities. The publisher of the book,
Praeger Publishers, New York, described the book as their best seller on the
subject in the United States, Canada and Europe.

 Member, The Council of Healthcare and Biotechnology Advisors, Gerson

Lehrman Group, New York, New York, which is a select group of distinguished
scientific and technical professionals carefully assembled by Gerson Lehrman
Group to provide paid healthcare and biotechnology market research, industry
recommendations, and consulting services worldwide.

 As Member, Technical and Drug Regulatory Committee, National

Pharmaceutical Alliance, Washington, D.C., was a strong advocate at meetings
of drug industry presidents for use of university facilities for industrial research
and development.
 Served as Member, Editorial/Advisory Board, Clinical Toxicology Consultant,
Contributing Editor, Methods and Findings in Experimental and Clinical
Pharmacology, Contributing Editor, Drugs of Today, and Contributing Editor,
Drugs of the Future.
 Several Honours and awards including biographical listings in over twenty
reference books such as, Men of Achievement, 1981, Who’s Who in Frontier
Science and Technology, 1984/1985, World Book of Honour, The Marquis
Who’s Who in the World, 7th Edition, The International Who’s Who of
Contemporary Achievement, 1984, Personalities of America, 1981/82,
Community Leaders of America, 12th Edition, 1981, 5,000 Personalities of the
World, Edition one, Two Thousand Notable Americans, International Book of
Honour, 1st World Edition, The Directory of Distinguished Americans, 1981,
International Who’s Who of Professionals, 2004 Edition.
 As entrepreneur and drug company president, negotiated U.S. defense
department DAPA contract to supply 194 SKU’s of pharmaceutical products to
Army, Navy, Air Force, and Marine hospitals nationwide for five years, secured
federal supply schedule contract to supply all 178 veterans administration
hospitals, all public health hospitals, all Indian health hospitals, and all 101
federal prisons throughout the United States, negotiated $110 million drug
supply contract with the federal government through SBA, and secured several
other drug supply contracts with the state of Texas and private sector agencies
such as university teaching hospitals and national drug wholesalers.

4
EMPLOYMENT HISTORY:

CURRENT POSITIONS: Executive Assistant to the Vice Chancellor, and Professor

of Pharmacology, Toxicology and Clinical Pharmacy,
University of Nigeria, Nsukka
February 1, 2006 to current

Chief Development Officer

University of Nigeria, Nsukka
April 2006 to current

President and Chief Executive Officer

University of Nigeria Research and Economic
Development (UNRED) Foundation, University of
Nigeria, Nsukka

Associate Chaplain
Christ Church Chapel (Anglican, Methodist and
Presbyterian)
University of Nigeria, Nsukka

PREVIOUS POSITIONS: President and Chairman of the Board

Universal Pharmacy Consultants, Inc.
4305 N. Garfield Street
Midland, Texas 79705
December 1999 to January 2006

President and Chairman of the Board

The Infinity Group, Inc.
4305 N. Garfield Street
Midland, Texas 79705
January 2000 to January 2006

President and Chairman of the Board

South Atlantic Petroleum, Inc.
4305 N. Garfield Street
Midland, Texas 79705
January 2000 to January 2006

Chairman, Board of Directors

Presidential Hotels Development Group, Inc., Dallas, TX

Chairman, Board of Directors

St. Pierre du Paris, Inc., Paris, Dallas, Milan

President and Chairman of the Board

PUNLABS QUALITY PRODUCTS, LTD
2500 Citywest Blvd., Suite 300, Houston, Texas 77042
January 1994 - December 1999
Punlabs was acquired by Universal Pharmacy
Consultants, Inc., in December 1999.
5
 President and Chairman of the Board
EBONY PHARMACEUTICAL MANUFACTURING, INC
Subsidiary, PUNLABS QUALITY PRODUCTS, LTD
10960 Stancliff Road, Houston, Texas 77099
September 1990 - December 1993
(Ebony Pharmaceutical Manufacturing, Inc. was merged
with PUNLABS (USA) in December 1993).

Managing Director and Chairman, Board of Directors

PUNLABS QUALITY PRODUCTS, LTD
10 Apllo Crescent, P.O. Box 7272 Jos, Nigeria
May 1985 - September 1990
(Punlabs (Nigeria) was acquired by Ebony
Pharmaceutical Manufacturing in September 1990).

Research Professor/Clinical Research Monitor

Clinical Research Department, Ayerst Laboratories
685 Third Avenue, New York, New York 10017
June 1983 – May 1985

Associate Professor of Pharmacology and Toxicology

St. John’s University, Jamaica, New York 11439
August 1981 – June 1983
Phone: (718) 990-6411

Director of Clinical Research and Assistant Professor of

Pharmacology and Toxicology
Florida A&M University, Tallahassee, Florida 32307
1979 - August 1981
Phone: (850) 599-3301

HONOURS: RECENT INTERNATIONAL AWARDS

1. “The 2008 Outstanding International Alumnus Award, University of Nebraska, Lincoln

Nebraska, USA”, awarded by the 2008 Alumni Awards Selection Committee, The
University of Nebraska.

2. “The 2006 Congressional Medal of Distinction”, awarded by the United States National
Republican Congressional Committee, Washington, D.C., USA.

3. “Man of the Year 2005”, awarded by The Governing Board of Editors of The American
Biographical Institute, Raleigh, North Carolina, USA.

4. “The 2005 President Ronald Reagan Republican Gold Medal”, awarded by the United
States National Republican Congressional Committee, Washington, D.C., USA.

5. “Business Man of the Year 2005”, awarded by the United States Business Advisory
Council, Washington, D.C., USA.

6
HONOURS: BIOGRAPHICAL LISTINGS IN REFERENCE BOOKS

1. Men of achievement, 1981

2. Who’s Who in Frontier Science and Technology, First Edition, 1984/85
3. World Book of Honour
4. Who’s Who in the World, 7th Edition, 1984/85
5. The International Who’s Who of Contemporary Achievement
6. Personalities of America, 1981-1982
7. Community Leaders of America, 12th Edition, 1981
8. International Who’s Who of Intellectuals, 1981
9. 5,000 Personalities of the World, Edition One
10. International Book of Honour, 1st World Edition
11. The Directory of Distinguished Americans, 1981 Edition
12. Two Thousand Notable Americans, 1st Edition
13. The International Register of Profiles, 6th Edition
14. International Who’s Who of Professionals, 2004 Edition
15. Empire Who’s Who: Empowering Executives and Professionals, 2004/05 Edition
16. Madison Who’s Who of Executives and Professionals Worldwide, 2004 Edition
17. Who’s Who in American Writing, 1982 Edition
18. Directory of International Biography, 17th Edition, 1980-1981
19. Who’s Who in the Midwest, 17th Edition, 1980-1981
20. Who’s Who in the South and Southwest, 18th Edition
21. Who’s Who in the East
22. Oxford’s Who’s Who
23. Who’s Who in Leading American Executives

HONOURS: SERVICES ON EDITORIAL/ADVISORY BOARD OF NATIONAL/

INTERNATIONAL SCIENTIFIC / MEDICAL JOURNALS

1. Contributing Editor, Methods and Findings in Experimental and Clinical Pharmacology

2. Contributing Editor, Drugs of Today
3. Contributing Editor, Drugs of the Future
4. Editorial/Advisory Board, Clinical Toxicology Consultant

MISCELLANEOUS HONOURS – PAST AND PRESENT

1. Best Student of the Year, 1970

2. Honour Roll, University of Nebraska, Lincoln
3. Phi Eta Sigma, National Academic Honourary for Men in American Universities
4. Award for research Excellence, University of Nebraska Medical Center, 1979
5. Member, Technical and Drug Regulatory Committee, National Pharmaceutical Alliance,
Washington, D.C.
6. Member, Education Committee, American College of Clinical Pharmacology
7. Member, National Board of advisors, American Biographical Institute
8. Fellow, American College of Clinical Pharmacology
9. Fellow, American Society of Consultant Pharmacists
10. Fellow, American College of Tropical Medicine
11. Rho Chi Society, National Pharmaceutical Honour Society
12. Sigmi Xi, Scientific Research Society of America
13. International Platform Association, 1981.
7
RESEARCH AREAS:

1. Cardiovascular Pharmacology; Clinical and Experimental Toxicology; Clinical

Medicine
2. Development of New Drugs from Plants and Other Natural Sources
3. Role of Trace Elements in Disease States
4. Development of New Antiarrhythmic Agents

NEW RESEARCH TECHNIQUES DEVELOPED:

1. A rapid in vivo technique for screening antiarrhythmic agents in mice. Arch. Int.
Pharmacodyn.Therapy, 229, 219 (1977

2. A rapid technique for identification of time of Myocardial Infarction Employing Tc-99

Pyrophosphate. Curr. Therapy Res. 30:122(1981)

OTHER INDEPENDENT RESEARCH PROJECTS COMPLETED AT THE UNIVERSITY

1. The antiarrhythmic activities of some new and selected Quinidine derivatives.

2. Effect of functional group substitutions at the 6’-Position on the antiarrhythmic activity
of Quinidine.
3. Structure-activity relationship studies of the effects of functional group changes at the
6’-Position on the acute toxicity profiles of Quinidine.
4. Clinical use of antiarrhythmic agents in mitral valve prolapse syndrome: rationale and
mechanisms of action.
5. Comparative hemodynamic studies of Quninidine and Cupreidine, a new Quinidine
derivative.
6. Comparative studies of the effects of Quinidine and Cupreidine on peripheral
vasculature.
7. Comparative studies on the effects of Quinidine and Cupreidine on the force of
myocardial contractility.

NEW COMPOUNDS (ANTIARRHYTHMICS) DEVELOPED THAT ARE PROTECTED

BY U.S. PATENTS:

1. 6’-Hydroxycinchonine
2. 6’-Benzyloxycinchonine
3. 6’-Allyloxycinchonine
4. 6’-Benzoyloxycinchonine
5. 6’-Isovaleryloxycinchonine
6. 6’-9-Dibenzoyloxycinchonine
7. 6’-Acetyloxycinchonine

8
SIGNIFICANT FEDERAL RESEARCH GRANTS:

A. Funded Research Grants

1. Development of new antiarrhythmic drugs. $142,662 (1981-1984)
National Institute of Health (NIH/MBS).

B. Approved, Not Funded

1. Antiarrhythmic-Hemodynamic Effects of Quinidine Analogs, $106,157.
National Institute of Health (National Heart, Lung and Blood Institute).

2. Minority Mental Health – Drug Abuse Training Program. $549,145.

National Institute of Mental Health.

3. Neutron Activation Analysis for Monitoring the Role of Cadmium in

Hypertension. $122,623. U.S. Department of Energy

RELEVANT INDUSTRY ADMINISTRATIVE EXPERIENCE (FROM 1983 TO 2006)

December 1999 – January 2006

1. President and Chairman of the Board, Universal Pharmacy Consultants, Inc.,

Midland, Texas.

Provided a variety of consultation services to the pharmaceutical industry, including

providing turnkey services in the establishment of pharmaceutical manufacturing plants,
training and providing management and technical staff on all aspects of the drug
manufacturing process, and providing consultation services on the process of new drug
development, such as clinical trials. Universal Pharmacy Consultants, Inc. is also
licensed by the Texas Department of Health as a wholesale distributor of Drugs, Foods
and Medical Devices; license number 0070628. In addition to the consulting services
provided to the pharmaceutical industry through Universal Pharmacy Consultants, Inc.,
I also currently serve as Member, The Council of Healthcare Advisors, Gerson Lehrman
Group, New York, New York, which is a select group of scientific and technical
professionals assembled by the Wall Street New York, New York, financial institution,
The Gerson Lehrman Group, to provide healthcare market research and consulting
services, worldwide.

2. President and Chairman of the Board, South Atlantic Petroleum, Inc., Midland,
Texas

Provided management and technical support to the petroleum industry, including

refineries. Also involved in the sale, purchase, and brokerage of crude oil. Experience
in the acquisition, development and management of oil wells in west Texas, and in the
deployment of excess oil field manpower and equipment from west Texas to Nigeria’s
petroleum industry. Recently entered into a Joint Venture partnership agreement with
Nalex International New York, New York for Nalex to work jointly with South Atlantic
Petroleum on various large developmental projects in the oil-rich country of Sao Tome,
West Africa. This Joint-venture initiative led to a very productive meeting on April 23,
2004, with the President of the country of Sao Tome.

9
3. President and Chairman of the Board, The Infinity Group, Inc., Midland, Texas

Developed the subsidiary corporation, Infinity Internet Systems, Ltd., which is an

Internet and Information Technology Company with the specific mission of developing
communication and information technology services in developing countries of the
world. Infinity Internet Systems, Ltd. has been licensed as an Internet Service Provider
(ISP) by the Nigerian Communication Commission (the Nigerian equivalent of United
States FCC) authorizing the company to provide Internet Services throughout Nigeria.
The University Council (board of Regents) of St. Paul’s University, Awka, Nigeria,
recently entered into a partnership agreement with the Infinity Group which allowed the
company to take over the computer building on the campus of the University which will
allow the company to establish and operate the largest and most efficient Internet
Service Provider (ISP) Company in West Africa. In addition, we have incorporated a
subsidiary company, Reliable Cyber Café, Ltd., which will operate a chain of
1,000 cyber cafes throughout the country to serve the communication needs, internet
education and computer training of the Nigerian general public. In addition to these,
under my leadership, on March 9, 2004, a subsidiary of The Infinity Group was
awarded a 2.9 billion naira (U.S. $25 million) contract to build the new national
headquarters of the National Association of Nurses and Midwives of Nigeria at Abuja,
Nigeria.

January 1994 – 1999

President and Chairman of the Board, Punlabs Quality Products, LTD., Houston,
Texas

Provided global and specific day-to-day management and technical guidance for all
phases of drug production, quality control, packaging, and marketing of a variety of
generic drug products. Secured and maintained all regulatory agency approvals and
licensure, including the U.S. food and Drug Administration Current Good
Manufacturing Practice (CGMP) inspections and approvals, the U.S. Drug Enforcement
Administration licensure for both manufacturing and wholesale distribution of
controlled substances in schedules 2 to 5, and also the required licensure by both Texas
Department of Health and Human Services and the Texas Department of Public Safety.
Development and implementation of a comprehensive standard operating procedure
(SOP) covering all aspects of the drug manufacturing process, quality control
procedures, and packaging / labeling operations. Responsibility for all budgetary and
fiscal administration, including funds acquisition, allocation and management.

Guided the company in vying for and winning several competitive government and
commercial sector contracts, including: The Defense Department awarded PUNLABS a
DAPA contract to supply 194 SKUs of pharmaceutical products to all Army, Navy, Air
Force, and Marine hospitals throughout the United States for a period of five years. The
Veteran’s Administration National Acquisition Center renewed PUNLABS’ Federal
Supply Schedule contracts, effective January 1, 1997. The limit of each purchase order
is $1,000,000 per VA hospital throughout the United States. There are 178 VA
hospitals. The Federal Supply Schedule contract also allows PUNLABS to supply all

10
101 federal prisons, all public health service hospitals, and all Indian health service
hospitals throughout the country. In addition to these opportunities, the Small Business
Administration issued to PUNLABS a contract support level totaling $110 Million in
U.S. federal government contracts. The State of Texas awarded PUNLABS 18 drug
products for supply to all state institutions for a period of one year. FHP, a California-
based National Health Care Provider (HMO) awarded six drug products to PUNLABS
to supply to FHP member institutions nationwide for a period of two years. PUNLABS
also has a one-year contract with the City of Houston and are still negotiating a sizable
drug supply contract with Sam’s Wholesale and Wal-Mart Stores. The University
Hospital Consortium, a buying group supplying nearly 100 University teaching
hospitals nationwide, has selected and approved PUNLABS as a vendor/supplier of
drug products to the buying group. PUNLABS is also an approved supplier of drug
products to several national wholesalers such as McKesson Drug Company and Bergen
Brunswig Drug Company. The past several years at PUNLABS provided a wonderful
opportunity for me to create a fine working environment and truly motivate, work with,
and lead the staff through several years of hard productive work, with minimal
operating funds.

September 1990 - December 1993

President and Chairman of the Board, EBONY PHARMACEUTICAL

MANUFACTURING, INC., Houston, Texas, subsidiary of PUNLABS Quality
Products, Ltd.

Development of the first generic drug pharmaceutical manufacturing plant in Houston,

the fourth largest city in the United States. EBONY PHARMACEUTICAL
MANUFACTURING, INC., was also the first and only generic drug manufacturing
company developed by a minority principal in the United States.

June 1985 - September 1990

Chairman of the Board, PUNLABS Quality Products, LTD., Jos, Nigeria

Development of one of the first few indigenous local drug manufacturing plants in
Nigeria. Within the first year of operation, the company secured three government drug
supply contracts, including a $3.4 million contract from the Defense Ministry to
manufacture and supply analgesics to the Army, Navy, and Air Force. PUNLABS
branded product for the Defense Ministry, DefadolTM, became the preferred analgesic
for the entire armed forces in Nigeria.

11
 June 1983 – May 1985

Research Professor/Clinical Research Monitor – Ayerst Laboratories, New York,

N.Y.

Clinical Research Scientist in charge of studies on antirrhythmic and inotropic agents

(and agents for other primary indications that needed to be evaluated for these effects as
a secondary indication) in the Cardiovascular Clinical Research Department of Ayerst
Laboratories. Responsibilities included preparing a clinical development plan (CDP)
for a new drug entering clinical investigation. Development of overall clinical research
grant / manpower cost projections for a new drug entering clinical studies, including
preparation of mini-CDP, protocol time track, development costs and support costs,
protocol design and development, budget preparation for individual protocols.
Investigator and site selection for clinical studies, site visit and investigator validation,
ordering and tracking medication for clinical trial development. Supervising medical
research associates in investigator site visit to monitor compliance to protocol
requirements, etc. Starting, monitoring and closing clinical investigations, coordinating
study reports of clinical investigations, etc.

SOME EXAMPLES OF SPECIFIC CLINICAL RESEARCH PROJECTS

COMPLETED AT AYERST LABORATORIES, NEW YORK, NEW YORK:

A. Inotropic Agents

- Writing a comprehensive Clinical Development Plan with 24 studies ranging from

early Phase I safety and efficacy studies in human volunteers, to late Phase III drug-
drug and drug-disease interaction studies. The CDP was authorized and this new
drug is in clinical development according to the CDP.
- Development of grant/manpower cost projects for AY-28, 768, including mini-CDP,
protocol time track, development according to the CDP.
- Writing an IND/NDA 1A priority classification for AY-28, 768, a new inotropic
agent.
- Writing Marketing Objectives and Scientific Affairs Objectives for development of
AY-28, 768, a new inotropic agent.
- Development of many study protocols for various studies outlined in the above
Clinical Development plan.
- Planning and ordering clinical supplies and study materials for various studies
outlined in the above CDP.

B. Hypertension Studies

- Development of study protocols for two hypertension studies and securing

authorization for the protocols (protocol numbers 83-038.CR and 83-101.CR)
- Budget preparation and securing budget approval for the hypertension studies
- Planning and ordering clinical supplies and study materials for the study
- Supervising clinical research associates in developing case report forms for the
studies
- Investigator contacts for initiation of the study, etc.

12
C. Arrhythmia Studies

- Betacor (new beta-adrenergic blocker)

- Development of study protocols (protocol numbers 81-141-CR and 84-052-CR) for
evaluation of the safety, tolerance and antiarrhythmic efficacy of Betacor in
ventricular and supraventricular arrhythmias, securing authorization for protocols
and ordering clinical supplies and study materials for the studies.
- Investigator contracts for initiation of the study, etc.

D. Specific Examples of Clinical Research Studies Designed and Study Protocols

Developed

1. Protocol 83-083-CR: Efficacy of Betacor in Mild-to-Moderate Hypertension (Step

One Therapy).
2. Protocol 83-103-CR: Efficacy of Betacor in Mild-to-Moderate Hypertension (Step
Two Therapy, with Thiazide).
3. Protocol 81-141-CR: Safety and Efficacy of Betacor in Supraventricular
Arrhythmias.
4. Protocol 84-053-CR: Safety and Efficacy of Betacor in Ventricular arrhythmias.
5. Protocol 83-220-CR: Safety of Acute Intravenous Administration of AY-28, 768 in
healthy volunteers.
6. Protocol 83-221-CR: Safety, Cardiodynamics and Kinetics of Single Rising
Intravenous Doses of AY-28-768 in patients with mild and moderate cardiac failure.
7. Protocol 83-222-CR: Safety of Acute Oral Administration of AY-28-768 oral
formulation in healthy volunteers.
8. Protocol 83-223-CR: Safety, Cardiodynamics and Kinetics of Single Rising Oral
Doses of AY-28-768 in patients with mild and moderate heart failure.
9. Protocol 83-224-CR: Safety, Tolerance, Kinetics and Cardiodynamics of Chronic
Oral Administration of AY-28-768 in patients with mild and moderate cardiac
failure.
10. Protocol 83-226-CR: Acute Hemodynamic Effects of Intravenous AY-28-768 in
patients undergoing cardiac catheterization.
11. Protocol 83-230-CR: Safety and Tolerance of Pelrinone in the Treatment of
Congestive Heart Failure.
12. Protocol 83-231-CR: Safety and Efficacy of Fixed Oral Doses of AY-28-768 in
patients with mild to moderate cardiac failure.

E. Some Examples of Specific Studies Completed

1. Protocol 83-220-CR: Safety of Acute Intravenous Administration of AY-28-768 in

healthy volunteers
2. Protocol 83-222-CR: Safety of Acute Oral Administration of AY-28-768 oral
formulation in healthy volunteers
3. Protocol 83-224-CR: Safety, Tolerance, Kinetics and Cardiodynamics of Chronic
Oral Administration of AY-28-768 twice daily in healthy patients.

13
UNIVERSITY ADMINISTRATIVE EXPERIENCE:

2006 – Current: Executive Assistant to the Vice Chancellor, University of Nigeria, Nsukka.
Chief Development Officer, University of Nigeria, Nsukka

President and CEO, University of Nigeria Research and Economic

Development (UNRED) Foundation, University of Nigeria, Nsukka.

1979-81 Director of Clinical Research, Florida A&M University, Tallahassee, Florida

UNIVERSITY TEACHING EXPERIENCE (FROM 1973 TO CURRENT), AND OTHER

RELEVANT ADMINISTRATIVE EXPERIENCES:

2006 – Current: Professor of Pharmacology, Toxicology and Clinical Pharmacy,

University of Nigeria, Nsukka.

1985-2006 Served as President, Chief Executive Officer, and Chairman Board of

Directors of a variety of companies in the United States, including 15
years as President and Chairman of the Board of a Pharmaceutical
Manufacturing Company in the United States of America.

1983-1985 Research Professor/Clinical Research Monitor, Ayerst Laboratories, New

York, New York.

1981-83 Associate Professor of Pharmacology and Toxicology

College of Pharmacy and Allied Health Professions, St. John’s University,
Jamaica, New York 11439
Courses taught included: Public Health, Biochemistry
Clinical Research Methodology
Pharmaceutical Technology
General Pharmacology
Supervisor: Professor Andrew J. Batulucci, Dean, College of Pharmacy

1979-81 Assistant Professor of Pharmacology and Toxicology

School of Pharmacy, Florida A&M University, Tallahassee, Florida
Courses taught included: Medical Pathology, Toxicology
General Pharmacology,
Clinical Research Methodology
Supervisor: Late Professor Charles Walker, Dean, College of Pharmacy

1975-79 Instructor/Graduate Teaching Assistant, Department of Medicinal Chemistry and

Pharmacognosy, College of Pharmacy, University of Nebraska.

1975 Instructor of Chemistry, State University of New York OCC Campus / Syracuse,
New York

1974 Instructor of Biology, School of Life Science

University of Nebraska at Lincoln
Supervisor: Professor Richard K. Boohar

14
1973-74 Research Associate in Chemistry, Radio-Chemistry Laboratory
University of Nebraska at Lincoln
Supervisor: Late Professor Edward P. Rack

1973-74 Proctor of Physics, Department of Physics

University of Nebraska at Lincoln
Supervisor: Professor Morgan

UNIVERSITY RESEARCH EXPERIENCE:

1979-81 Development of New Antiarrhythmic Drugs; Role of Cadmium and Zinc in

Hypertension, Florida A&M University, Tallahassee, Florida

1976-79 Research in Cardiovascular Pharmacology, Toxicology and Clinical Medicine

University of Nebraska Medical Center, Omaha

1975-76 Development of Rapid In Vivo Technique for Screening Antiarrhythmic Agents

University of Nebraska at Lincoln

1973-74 Research in the development of new analytical technique for quantitative

measurement of aluminum in biological samples, employing neutron activation
analysis, University of Nebraska at Lincoln

PLEASE SEE PAGES 8 AND 9 OF THIS CURRICULUM VITAE FOR SPECIFIC

RESULTS OF UNIVERSITY RESEARCH EXPERIENCE, INCLUDING:

 NEW RESEARCH TECHNIQUES DEVELOPED (PAGE 8)

 OTHER INDEPENDENT RESEARCH PROJECTS
COMPLETED AT THE UNIVERSITY (PAGE 8)
 NEW COMPOUNDS (ANTIARRHYTHMIC) DEVELOPED
THAT ARE PROTECTED BY U.S. PATENTS (PAGE 8)
 FEDERAL RESEARCH GRANTS (PAGE 9)

PROFESSORS AND RESEARCH SCIENTISTS AT IVY LEAGUE UNIVERSITIES

WHO HAVE QUOTED MY RESEARCH RESULTS TO VALIDATE THEIR
RESEARCH, OR USED A TECHNIQUE I DEVELOPED AS A MODEL IN THEIR
RESEARCH

A. HARVARD UNIVERSITY MEDICAL SCHOOL

Prof. Colin T. Maguire
Prof. Wakimoto Hiroko
Prof. Peter F. Hammer
Prof. Kimberlee Gauvreau
Prof. Charles I. Berul

15
Reference/Citation:
Colin T. Maguire, Wakimoto Hiroko, Vickas V. Patel, Peter F. Hammer, Kimberlee Gauvreau
and Charles I. Berul: “Implications of ventricular arrhythmia vulnerability during murine
electrophysiology studies”. Physiol. Genomics 15: 84-91, (2003).

B. CORNELL UNIVERSITY MEDICAL SCHOOL

Prof. Dennis Drayer

Reference/Citation:

Drayer, D.E., Lowenthal, D.T., Restivo, K.M., Schwartz, A., Cook, E.C., and Reidenberg,
M.M.: Steady-State Serum Levels of quinidine and active metabolites in cardiac patients with
varying degrees of renal function. Clin. Pharmacol Ther. 24:31 (1978).

C. UNIVERSITY OF PENNSYLVANIA MEDICAL SCHOOL

Prof. Vickas V. Patel

Reference/Citation:
Colin T. Maguire, Wakimoto Hiroko, Vickas V. Patel, Peter F. Hammer, Kimberlee Gauvreau
and Charles I. Berul: “Implications of ventricular arrhythmia vulnerability during murine
electrophysiology studies”. Physiol. Genomics 15: 84-91, (2003).

POST GRADUATE STUDENTS MENTORED/SUPERVISED

A. M.Sc Students

1. Andrew A. Weaver, B.S. Pharm., M.Sc (1981)

Published Project: “A Rapid Technique for Identification of Time of Myocardial
Infarction Employing Tc-99 Pyrophosphate”. Current Therapeutic
Research 30: 122 (1981).

B. Doctor of Pharmacy (Pharm.D) Students

1. Lynn C. Twiggs, B.S. Pharm., Pharm.D (1981)
Published Project: “The Effects of Parenteral Nutrition on Tumor Response”. Amer. J.
Intravenous Therap. and Clin. Nutrition. 9, 5:10 (1981).

2. Kenneth P. Kumer, B.S. Pharm., Pharm.D (1981)

Published Project: “Pharmacokinetic Considerations in Pediatric Digoxin Dosing”.
Current Therapeutic Research 30:265 (1981)

3. Geraldine Roberts, B.S. Pharm., Pharm.D (1982)

Published Project: “The Patient’s Right to Non compliance”. Contemporary Pharmacy

Practice 5, 3:204 (1982)

16
4. John E. Clark, B.S. Pharm., Pharm.D (1982)

Published Project: “Legal Aspects of Clinical Pharmacy Practice”. Contemporary

Pharmacy Practice 5, 3: 198 (1982)

5. Vanita G. Williams, B.S. Pharm., Pharm.D (1983)

Published Project: “Systemic Lupus Erythematosis: Symptoms, diagnosis and

Management”. Clinical Toxicology Consultant 6:10-20 (1985)

6. Gail C. Vernado, B.S. Pharm., Pharm.D (1983)

Published Project: “Perspectives on the Clinical Pharmacology of Benzodiazepines

“Drugs of Today Vol. 21, No.1 (1985)

C. Ph.D Students

1. Timothy Nwako, Ph.D

Was completing his Ph.D dissertation when I left the university to join the
Cardiovascular Clinical Research Department at the World Headquarters of AYERST
LABORATORIES in New York, New York.

MEMBERSHIP IN PROFESSIONAL SOCIETIES (PAST AND PRESENT):

1. Fellow, American College of Clinical Pharmacology

2. Fellow, American Society of Consultant Pharmacists
3. Fellow, American College of Tropical Medicine
4. American Federation for Clinical Research
5. Sigma Xi
6. Rho Chi
7. American Pharmaceutical Association
8. Academy of Pharmaceutical Sciences
9. American Association of Colleges of Pharmacy
10. American Association for the Advancement of Science
11. Union of African Societies of Pharmacology
12. International Platform Association
13. National Pharmaceutical Alliance
14. New York Academy of Science
15. The Smithsonian Institute, Washington, D.C.
16. Drug Information Association
17. American Heart Association

SELECTED INVITED PROFESSIONAL PRESENTATIONS:

1975:
“New Dimensions in Pharmacological Research – Neutron Activation Analysis.”
To faculty and graduate students, Department of Pharmacology
Upstate Medical Center, Syracuse, New York

17
1976:
“Trends in Cardiac Glycosides Toxicity”. To faculty and graduate students, University of
Nebraska, College of Pharmacy, Omaha, Nebraska

1977:
“A Preliminary Evaluation of 6’-Hydroxycinchonine As An Antiarrhythmic Agent.” To the
American Society of Pharmacology and Experimental Therapeutics at Columbus, Ohio

1978:
“Use of Antiarrhythmics in Mitral Valve Prolapse: Rationale and Mechanisms of Action.”
At a clinical conference for physicians at Nebraska Methodist Hospital, Omaha, Nebraska

1979:
“A Comparative Study on the Acute Toxicity Profile of Quinidine and Five New Analogs in
Mice.” To the American Society of Pharmacology and Experimental Therapeutics at Portland,
Oregon

1980:
“A Comparative Study on the Antiarrhythmic Activity, Acute Toxicity Profile and
Hemodynamic Properties of Quinidine Analogs.” American Federation for Clinical Research,
(MSMRF-X1) at Indianaposlis, Indiana

“A Comparative Study on Some Hemodynamic Properties of Quinidine and Cupredine.” At the

1980 Federation Meeting, Anaheim, California

“Use of University Facilities for Industrial Research and Development.” To Drug Industry
Presidents, 1980 Annual Meeting of National Pharmaceutical Alliance at Louisville, Kentucky

1981:
“A Comparative Study of the Antiarrhythmic Activity and Acute Toxicity Profiles of Quinidine
and Four New Quinidine Analogs.” To faculty and pharmacy students, College of Pharmacy
and Pharmaceutical Science, Howard University, Washington, D.C.

1982:
“The Process of New Drug Development: Current Deficiencies and Opportunities for
Improvement.” At a National Symposium on Current Concepts and Strategies in Clinical
Research, Waldorf-Astoria, New York City

1983:
“Development of New Drugs.” NBC national television on health fields, April 25 / July 25,
1983

1984:
“Modification of Drug Properties Through Pro Drugs and Analogs.” To Drug Industry
Presidents, 1984 Annual Meeting of National Pharmaceutical Alliance at Atlanta, Georgia

18
CONSULTANT POSITIONS AND COMMUNITY SERVICES (PAST AND PRESENT):

1. Editorial/Advisory Board, Clinical Toxicology Consultant

2. Program Director, National Symposium on Concepts and Strategies in Clinical
Research October 3-6, 1982, at Waldorf-Astoria, New York City
3. Program Director, NBC National Television Services on New Drug Development (NBC
host Frank Fields). Program numbers 4/77 to 4/81 on health fields
4. Member, Technical and Regulatory Committee, National Pharmaceutical Alliance,
Washington, D.C.
5. Member, Education Committee, American College of Clinical Pharmacology
6. Member, National Board of advisors, American Biographical Institute
7. Member, Doctor of Pharmacy (Pharm.D.) Program Advisory Board St. John’s
University, New York
8. Continuing Education Provider, Florida Pharmaceutical Association
9. Visiting Faculty, Oak Ridge Associated Universities, Oak Ridge National Laboratories
Oak Ridge
10. Charter Member, C.K. Steel Chapter, United States Jaycees, Tallahassee, Florida
11. Member, Board of Trustees, Calvary Baptist Church, Omaha, Nebraska
12. Contributing Editor, Methods and Findings in Experimental and Clinical Pharmacology
13. Contributing Editor, Drugs of Today
14. Contributing Editor, Drugs of the Future
15. Consultant to the American Board of Tropical Medicine for the Development of the
American Journal for Tropical Medicine
16. Consultant to J.R. Prous, S.A., Barcelona, Spain, for the development of the
International Journal of Clinical Observations

PUBLICATIONS:

A. BOOKS

1. Concepts and Strategies in New Drug Development, by P.U. Nwangwu, Pharm.D.,

Ph.D., Praeger Publishers, New York (1983)

B. FULL MANUSCRIPTS

1. Nwangwu, P.U., Hocslaw, T.L., and Stohs, S.J. “A Rapid in vivo Technique for
Preliminary Screening of Antiarrhythmic Agents in Mice.” Arch. Int. Pharmacodyn.
Therap, 229,219 (1977)

2. Nwangwu, P.U., “The Antiarrhythmic Activities, Acute Toxicity Profile and

Hemodynamic Properties of some New and Selected Quinidine Analogs.” Doctoral
Dissertation, University of Nebraska Medical Center, Omaha, Nebraska (1979)
University Microfilms International. Order No. 8010544

3. Nwangwu, P.U., Holsclaw, T.L., Rosenberg, H., Small, L.D., and Stohs, S.J. “The
Antiarrhythmic Activities of 6’-Hydroxycinchonine, 6’-Benzyloxycinchonine and 6’-
Allyloxycinchonine as Compared to Quinidine in Mice. J. Pharm. Pharmacol. 46, 301
(1979)

19
4. Hamilton, C.A., Nwangwu, P.U., Parkinson, S., Rapport, J., and Stohs, S.J. “Mitral
Valve Prolapse Syndrome: A Six Month Follow Up Study of Propranolol Theraphy.”
Nebraska Medical Journal 46, 301 (1979)

5. Small, L. D., Rosenberg, H., Nwangwu, P.U., Holcslaw, T.L., and Stohs, S.J. “Partial
Synthesis of 6’-Hydroxycinchonine and Its Antiarrhythmic Activity in Mice.” J. Med.
Chem. 22, 11014 (1979)

6. Nwangwu, P.U., “Current Concepts on the Uses and Side Effects of L-Tryptophan.” Fl.
Pharm. J. 44, 10, 7 (1980)

7. Nwangwu, P.U., “The Uses of Parenteral Phenytoin in Piggybacks.” Fl. Pharm. J. 44,
10, 7 (1980)

8. Nwangwu, P.U., “The Clinical Toxicology of Quinidine.” Clinical Toxicology

Consultant 2,4 (1980)

9. Nwangwu, P.U., Meresh, K., Holcslaw, T.L., Rosenberg, H., Small, L.D., and Stohs, S.J.
“A Comparative Study on the Antiarrhythmic Activity and Acute Toxicity Profile of
Quinidine and Four New Analogs in Mice.” Toxicology, 16, 73 (1980)

10. Nwangwu, P.U., and Petruconis, S.K.: “A Therapeutic Profile on Dobutamine.” Fl.
Pharm J. 44,6,11 (1980)

11. Battles, K., German, M.R., and Nwangwu, P.U., “Merieux rabies Vaccine (Human
Diploid Cell Vaccine).” Fl. Pharm. J. 45, 2:8 (1981)

12. Ingram, N., German, M.R., and Nwangwu, P.U., “Use of Betamethasone and
Dexamethasone to Prevent Neonatal RDS.” Fl. Pharm. J. 45 5:14 (1981)

13. Kumer, K. and Nwangwu, P.U., “Bruton’s Agammaglobulinemia: Etiology, Diagnosis

and Clinical Management.” Current Therapeutic Research 29:335 (1981)

14. Kumer K. and Nwangwu, P.U., “Pharmacokinetic Consideration in Pediatric Digoxin

Dosing.” Current Therapeutic Research 30: 265 (1981)

15. Kumer, K. and Nwangwu, P.U., “Parenteral Drug Abuse: Clinical Toxicology and
Sequelae.” Clinical Toxicology Consultants 3:119 (1981)

16. Kumer, K. and Nwangwu, P.U., “Clinical Toxicology of Warfarin from Commercial
Rodenticides: Symptoms, Diagnoses and Management.” Clinical Toxicology
Consultants 3,1:23 (1981)

17. Nwangwu, P.U., Hamilton, C.A., and Stohs, S.J. “Use of Antiarrhythmics in Mitral
Valve Prolapse Syndrome: Rationale and Mechanisms of Action.” Current Therapeutic
Research, 29,126 (1981)

18. Nwangwu, P.U., Stohs, S.J., Rosenberg, H., Small, L.D., and Holcslaw, T.L., “The
Antiarrhythmic Activity of 6’-Benzoyloxycinchonine, A New Quinidine Derivative.”
Current Therapeutic Research 29:416 (1981)

19. Nwangwu, P.U., “The Pharmacodynamics of Inflammation and Perspectives on Use of

Steroids.” Current Therapeutic Research 30:253 (1981)

20
20. Nwangwu, P.U., Stohs, S.J., Rosenberg, H., and Small, L.D., “Effects of Functional
Group Substitutions at the 6’-Position on the Antiarrhythmic Activity of Quinidine.”
Current Therapeutic Research 30:479 (1981)

21. Twiggs, L.C. and Nwangwu, P.U., “The Effects of Parenteral Nutrition on Tumor
Response.” Amer. J. Intravenous Therap. And Clin. Nutrition. 9, 5:10 (1981)

22. Weaver, A. and Nwangwu, P.U., “A Rapid Technique for Identification of Time of
Myocardial Infarction Employing Tc-99 Pyrophosphate.” Current Therapeutic
Research, 30:122 (1981)

23. Mangione, R.A. and Nwangwu, P.U., “Food Poisoning, Diagnosis and Management.”
Clinical Toxicology Consultant 4, 4:123 (1982)

24. McGuire, L., Clyne, K.E., and Nwangwu, P.U., “Perspectives on Hetastarch, A New
Plasma Expander.” Fl. Pharm. J. 46, 1:7 (1982)

25. Roberts, G. and Nwangwu, P.U., “The Patient’s Right to Non-compliance.”

Contemporary Pharmacy Practice, 5, 3:204 (1982)

26. Twiggs, L.C. and Nwangwu, P.U., “Perspectives on the Peripheral Use of Fructose
Containing Hypertonic Solutions in Nutritional Support.” Amer. J. Intravenous Therap.
and Clin. Nutrition 9 No. 2:9 (1982)

27. Nwangwu, P.U., Holcslaw, T.L., Stohs, S.J., Rosenberg, H., Small, L.D., and Modrak, J.
B., “Hemodynamic Properties of New Quinidine Analog Cupreidine (6’-
Hydroxycinchonine).” J. Cardiovasc. Pharmacol. 4:124 (1982)

28. Nwangwu, J.T., Clark, J.E., and Nwangwu, P.U., “Adverse Effects of Cigarette
Smoking on the Pharmacological Actions of Some Drugs.” Clinical Toxicology
Consultants 4:80 (1982)

29. Clark, J.E. and Nwangwu, P.U., “Legal Aspects of Clinical Pharmacy Practice.”
Contemporary Pharmacy Practice 5, 3:198 (1982)
30. Kumer, K., Nwangwu, J.T., and Nwangwu, P.U., “Perspectives on Digoxin Absorption
from Small Bowel Resections.” Drug Intelligence and Clinical Pharmacy 17-121 (1983)

31. Nwangwu, P.U., “The Process of New Drug Development: Current Deficiencies and
Opportunities for Improvement.” In Concepts and Strategies in New Drug
Development, Nwangwu, P.U. (Ed.) Praeger Publishers, New York (1983)

32. Radonic, L.P., Mangione, R.A., and Nwangwu, P.U., “Toxic Shock Syndrome: Clinical
Manifestations and Management.” Clinical Toxicology Consultant 5:1-9 (1983)

33. Twiggs, L.C. and Nwangwu, P.U., “Clinical Management of the Digoxin-Quinidine
Interaction.” Clinical Toxicology Consultant Vol. 6 (1985)

34. Williams, V.G. and Nwangwu, P.U., “Systemic Lupus Erythematosis: Symptoms,
diagnosis and Management.” Clinical Toxicology Consultant 6:10-20 (1985)

21
35. Williams, V.G., Vernado, G.C., and Nwangwu, P.U., “Perspectives on the Clinical
Pharmacology of Benzodiazepines.” Drugs of Today Vol. 21, No. 1 (1985)

C. PUBLISHED ABSTRACTS OF PRESENTATIONS AT INTERNATIONAL

PROFESSIONAL CONFERENCES ATTENDED

1. Nwangwu, P.U., Holcslaw, T.L., Small, L.D., and Stohs, S.J., “A Preliminary Evaluation
of 6’-Hydroxycinochonine as Antiarrhythmic Agent.” Pharmacologist 19 141 (1977)

2. Nwangwu, P.U., Meresh, K., Holcslaw, T.L., Rosenbert, K., Small, L.D., and Stohs, S.J.,
“A Comparative Study on the Toxicity Profile of Quinidine and Four New Quinidine
Analogs in Mice.” Pharmacologist 21, 223 (1979)

3. Rosenberg, H., Small, L.D., Nwangwu, P.U., Maresh, K., Small, L.D., and Stohs, S.J.,
“Synthesis of 6’-Hydroxycinochonine Esters and their Antiarrhythmic Activities in
Mice.” Apha Acad. Pharm. Sci. 9, 121 (1979)

4. Nwangwu, P.U., Holcslaw, T.L., Stohs, S.J. Rosenberg, H., and Small, L.D., “A
Comparative Study of Some Hemodynamic Properties of Quinidine and Cupreidine (6’-
Hydroxxycinchonine) Fed. Pro. 39, 3, 1106 (1979)

5. Nwangwu, P.U., “A Comparative Study on the Antiarrhythmic Activity, Acute Toxicity

Profile, and Hemodynamic Properties of Quinidine and Cupreidine, A New Quinidine
Analog.” Clinical Research 28, N. 4, 801a (1980)

6. Pennick, W., Howard, E., Holder, M.S., and Nwangwu, P.U., “Contribution of
Angiotensin II, Calcium and Norepinephrine to Ventricular Hypertrophy.” Clinical
Research 29:4, 800a (1981)

7. Weaver, A., Nwangwu, P.U., and Tookes, M.A. “Double Myocardial Infarct
Localization of Technetium-99mm Pyrophosphate in Rodents.” Clinical Research 29:4
(1981)

D. TECHNICAL REPORTS/BOOKS REVIEWED FOR MEDICAL JOURNALS

1. Applied Therapeutics for Clinical Pharmacists, 2nd Ed., Edited by Mary Anne Koda-
Kimble, Pharm.D., Brian S. Katcher, Pharm.D., and Lloyd Y. Young, Pharm.D., 944
pages (Price: $31.50). (Published in J. Fl. Med. Assoc., Vol.67, No. 10, 951) (1980)

2. Pharmacological and Toxicological Perspectives of Commonly Abused Drugs, by D.

Inaba, Pharm.D., E.L. Way, Ph.D., and S.W. School, M.D., Ph.D., 43 pages. National
Drug Abuse Center, Medical Nomograph Series, Published in J. Fl. Med. Assoc., Vol.
67 No. 67 No 10, 96’ (1980)

22
NAMES AND ADDRESSES OF THREE REFEREES:

1. Professor Chinedu O. Nebo, Ph.D

Former Vice Chancellor
University of Nigeria
Nsukka
Phone: 08037154855

2. Professor Dora Akunyili, Ph.D., OFR

Honourable Minister of Information and Communication
Federal Ministry of Information and Communication
Abuja
Phone: 08034700560

3. Honourable Ifediora Amobi, Ph.D

Senior Special Assistant on National Development Matters
Office of the Vice President, Federal Republic of Nigeria
Abuja
Phone: 08037221674

23
 THE CURRICULUM VITAE

OF

PROF. PETER U. NWANGWU, Pharm. D., Ph.D.

24